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Abstract
Background: This study tested the superiority of combined cyclosporine A (CsA)-erythropoietin (EPO) therapy
compared with either one in limiting brain infarction area (BIA) and preserving neurological function in rat after
ischemic stroke (IS).
Methods: Fifty adult-male SD rats were equally divided into sham control (group 1), IS plus intra-peritoneal
physiological saline (at 0.5/24/48 h after IS) (group 2), IS plus CsA (20.0 mg/kg at 0.5/24h, intra-peritoneal) (group 3),
IS plus EPO (5,000IU/kg at 0.5/24/48h, subcutaneous) (group 4), combined CsA and EPO (same route and dosage as
groups 3 and 4) treatment (group 5) after occlusion of distal left internal carotid artery.
Results: BIA on day 21 after acute IS was higher in group 2 than in other groups and lowest in group 5 (all p <
0.01). The sensorimotor functional test showed higher frequency of left turning in group 2 than in other groups
and lowest in group 5 (all p < 0.05). mRNA and protein expressions of apoptotic markers and number of apoptotic
nuclei on TUNEL were higher in group 2 than in other groups and lowest in group 1 and 5, whereas the anti-
apoptotic markers exhibited an opposite trend (all p < 0.05). The expressions of inflammatory and oxidized protein
were higher in group 2 than in other groups and lowest in group 1 and 5, whereas anti-inflammatory markers
showed reversed changes in group 1 and other groups (all p < 0.05). The number of aquaporin-4+ and glial
fibrillary acid protein+ stained cells were higher in group 2 as compared to other groups and lowest in groups 1
and 5 (all p < 0.01).
Conclusion: combined treatment with CsA and EPO was superior to either one alone in protecting rat brain from
ischemic damage after IS.
Background
Despite current advances in medicine and implementa-
tion of the state-of-the-art management guidelines,
ischemic stroke (IS) remains the leading cause of death
in the industrial countries regardless of etiologies [1-4].
Indeed, this unsavory clinical problem has vexed neurol-
ogists for decades. Not only the death but also the high
incidence of severe neurological impairment after IS
with permanent disability [5] that cause a tremendous
social economic burden worldwide. Although growing
data indicate that the newly developed thrombolytic
therapy offers a promising treatment option for some
patients with acute IS early after the onset of symptoms
[6,7], its clinical application is impeded by major limita-
tions [7-10]. Besides, thrombolytic therapy has been
reported to be associated with a relatively high incidence
of intracranial hemorrhage [10,11] contributing to its
notable mortality and morbidity. Accordingly, the treat-
ment of acute IS patients remains problematic. There-
fore, finding a safe and effective therapeutic regimen for
patients following acute IS, especially for those unsuita-
ble for thrombolytic therapy, is of utmost importance
for physicians.
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reported to enhance erythropoiesis in the treatment of
anemia, but it has also been shown to alleviate ische-
mia-related organ dysfunction through anti-ischemic
and cellular protective effects [12-15]. Our recent stu-
dies [16,17] have further shown that EPO therapy
remarkably improves neurological impairment in rat IS
model and clinical outcome in patients after acute IS.
Additionally, accumulating evidence from animal models
indicates that not only does cyclosporine A (CsA) pos-
sess immunosuppressive properties, but it is also a
potent inhibitor of mitochondrial permeability transition
pore (mPTP) that plays an important role in attenuating
ischemia-reperfusion injury [18-20]. Recently, a clinical
observational study [21] and an experimental investiga-
tion using a mini-pig animal model [22] demonstrated
that administration of CsA after acute ST-segment ele-
vation myocardial infarction (STEMI) effectively limited
left ventricular infarct size. However, whether combined
therapy with CsA and EPO will maximize the anti-
ischemic effect and further improve outcome after acute
IS remains uncertain. In view of the fact that there is no
effective therapy for the majority of patients with acute
I Sa n dt h a tb o t hE P Oa n dC s Ah a v eb e e ns h o w nt o
offer therapeutic benefit to this patient population, this
study investigated whether combined therapy with these
two drugs was superior to either one alone in reducing
brain infarction and improving neurological function in
a rat acute IS model.
Methods
Ethics
A l la n i m a le x p e r i m e n t a lp rocedures were approved by
the Institute of Animal Care and Use Committee at our
institute and performed in accordance with the Guide
for the Care and Use of Laboratory Animals (NIH publi-
cation No. 85-23, National Academy Press, Washington,
DC, USA, revised 1996).
Animal Model of Acute Ischemic Stoke and Corner Test
The protocol and procedure of using a rodent model of
acute IS has been described in details in our recent
report [23]. Adult male Sprague-Dawley rats, weighing
300-325 g (Charles River Technology, BioLASCO Tai-
wan Co., Ltd., Taiwan) were utilized in the current
study. All animals were anesthetized by chloral hydrate
(35 mg/kg i.p.) and placed in a supine position on a
warming pad at 37°C. After exposure of the left com-
mon carotid artery (LCCA) through a transverse neck
incision, a small incision was made on the LCCA
through which a nylon filament (0.28 mm in diameter)
was carefully advanced into the distal left internal caro-
tid artery for occlusion of left middle cerebral artery
(LMCA) to induce brain infarction of its blood-
supplying area. The nylon filament was removed three
hours after occlusion, followed by closure of the muscle
and skin in layers. The rats were then placed in a porta-
ble animal intensive care unit (ThermoCare
®)f o r2 4
hours. The sensorimotor functional test (Corner test)
was done for each rat at baseline and on day 1 (24 h
after procedure), 3, 7, 14, and 21 after acute IS induction
as we recently described [16,23]. Briefly, the rat was
allowed to walk through a tunnel and then into a corner,
the angle of which was 60 degrees. To exit the corner,
the rat could turn either to left or right. The results were
recorded by a technician who was blind to the study
design. This test was repeated 10 to 15 times with at least
30 seconds between each trial. We recorded the number
of right and left turns from 10 successful trials for each
animal and used the results for statistical analysis.
Treatment Protocol
Ten sham-operated healthy rats served as normal con-
trols (group 1). The other 40 rats with acute IS were
equally divided into IS plus intra-peritoneal 1.0 mL phy-
siological saline (at 0.5, 24 and 48 hour after IS) (group
2, n = 10), IS plus CsA (20.0 mg/kg at 0.5 and 24 hour,
intra-peritoneal) (group 3, n = 10), IS plus EPO (5,000
IU/kg at 0.5, 24, and 48 hour, subcutaneous) (group 4, n
= 10), and combined CsA (20.0 mg/kg at 0.5 and 24
hour, intra-peritoneal) and EPO (5,000 IU/kg at 0.5, 24
and 48 hour, subcutaneous) treatment (group 5, n = 10).
Two rats died in group 2 and one rat died in each
other group (i.e. groups 3 to 5) during the procedure.
For the purpose of this study, additional rats were
added so that 10 animals in each group went through
the whole study.
The dosage of EPO and the timing of treatment were
based on previous literature and our recent report
[16,24], whereas the dosage of cyclosporine and the treat-
ment protocol were according to a previous report [25].
Specimen Collection and Preparation for Individual Study
Rats in all groups were euthanized on day 21 after IS
induction, and the brain of each rat was promptly
removed and immersed in cold saline. For immunohis-
tofluorescent (IHF) study, the brain tissue was rinsed
with PBS, embedded in OCT compound (Tissue-Tek,
Sakura, Netherlands) and snap-frozen in liquid nitrogen
before being stored at -80°C. For immunohistochemical
(IHC) staining, the brain tissue was fixed in 4% formal-
dehyde and embedded in paraffin. Additionally, the
brain tissue of infarct area was collected for Western
blot, real-time PCR, and oxidative stress analyses.
Measurement of Brain Infarct Area
To evaluate the impact of CsA, EPO, and combined
EPO and CsA treatment on brain infarction, coronal
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Page 2 of 14sections of the brain were obtained from six extra ani-
mals in groups 2 to 5 (n = 6 for each group) as 2 mm
slices. Each cross section of brain tissue was then
stained with 2% 3,5-Triphenyl-2H-Tetrazolium Chloride
(TTC) (Alfa Aesar) for BIA analysis. The methodology
has been described in details in our recent studies
[16,23]. Briefly, all brain sections were placed on a tray
with a scaled vertical bar to which a digital camera was
attached. The sections were photographed from directly
above at a fixed height. The images obtained were then
analyzed using Image Tool 3 (IT3) image analysis soft-
ware (University of Texas, Health Science Center, San
Antonio, UTHSCSA; Image Tool for Windows, Version
3.0, USA). BIA was identified as either whitish or pale
yellowish regions. Infarct region was further confirmed
by microscopic examination. The percentages of infarct
area were then calculated by dividing the area with total
cross-sectional area of the brain.
All measurements (i.e. Corner test and assessment of
BIA) were performed by a skillful senior technician
blinded to the treatment and non-treatment groups.
TUNEL Assay for Apoptotic Nuclei
For each rat, six sections of BIA were analyzed by an in
situ Cell Death Detection Kit, AP (Roche) according to
the manufacturer’s guidelines. Three randomly chosen
high-power fields (HPFs) (×400) were observed for
terminal deoxynucleotidyl transferase-mediated 2’-deox-
yuridine 5’-triphosphate nick-end labeling (TUNEL)-
positive cells for each section. The mean number of
apoptotic nuclei per HPF for each animal was obtained
by dividing the total number of cells with 18.
Immunofluorescent Staining
Frozen sections (4 μm thick) were obtained from BIA of
each animal. The sections were fixed with 4% parafor-
maldehyde and permeated with 0.5% Triton X-100 and
then incubated with antibodies against NeuN (1:1000,
Millipore), GFAP (1:500, DAKO), PGC-1a (1:100, Santa
cruz), and AQP4 (1:200, abcam) at 4°C overnight. Alexa
Fluor488, Alexa Fluor568, or Alexa Fluor594-conjugated
goat anti-mouse or rabbit IgG were used to localize sig-
nals. Sections were then counterstained with DAPI and
observed with a fluorescent microscope equipped with
epifluorescence (Olympus IX-40).
Western Blot Analysis for Bax, Cytochrome C, Caspase 3,
NADPH oxidase 1 (NOX-1), NOX-2, Inducible Nitric Oxide
Synthase (iNOS), and Endothelial (e)NOS
Equal amounts (50 mg) of protein extracts were loaded
and separated by SDS-PAGE using 12% acrylamide gra-
dients. After electrophoresis, the separated proteins
were transferred electrophoretically to a polyvinylidene
difluoride (PVDF) membrane (Amersham Biosciences).
Nonspecific sites were blocked by incubation of the
membrane in blocking buffer [5% nonfat dry milk in T-
TBS (TBS containing 0.05% Tween 20)] for overnight.
The membranes were incubated with the indicated pri-
mary antibodies (Bax, 1:1000, abcam; Cytochrome C,
1:2000, BD; Caspase, 1:3000, abcam; NOX-1, 1:1500,
Sigma; NOX-2, 1:500, Sigma; iNOS, 1:200, abcam;
eNOS, 1:1000, 1:500, abcam; Actin, 1:10000, Chemicon)
for 1 hr at room temperature. Horseradish peroxidase
-conjugated anti-rabbit or anti-mouse immunoglobulin
IgG (1:2000, Cell Signaling) was used as a second
antibody for 1 hr at room temperature. The washing
procedure was repeated eight times within 1h, and
immunoreactive bands were visualized by enhanced che-
miluminescence (ECL; Amersham Biosciences) and
exposure to Biomax L film (Kodak). For purposes of
quantitation, ECL signals were digitized using Labwork
software (UVP).
Protocol for RNA Extraction
Lysis/binding buffer (High Pure RNA Tissue Kit, Roche,
Germany) 400 μL and an appropriate amount of frozen
brain tissues were added to a nuclease-free 1.5 mL
microcentrifuge tube, followed by disruption and homo-
genization of the tissue by using a rotor-stator homoge-
nizer (Roche).
For each isolation, 90 mL DNase incubation buffer
was pipetted into a sterile 1.5 mL reaction tube, 10 mL
DNase I working solution was then added, mixed and
incubated for 15 min at 25°C. Wash buffer I 500 mL
was then added to the upper reservoir of the filter tube,
which was then centrifuged for 15 seconds at 8,000g.
Wash buffer II 300 mL was added to the upper reservoir
of the filter tube, which was centrifuged for 2 min full-
s p e e da ta p p r o x i m a t e l y1 3 , 0 0 0 g. Elution Buffer 100 mL
was then added to the upper reservoir of the filter tube.
Finally, the tube assembly was centrifuged for 1 min at
8,000g, resulting in eluted RNA in the microcentrifuge
tube.
Real-Time Quantitative PCR Analysis
Real-time polymerase chain reaction was conducted
using LighCycler TaqMan Master (Roche, Germany) in
a single capillary tube according to the manufacturer’s
guidelines for individual component concentrations.
Forward and reverse primers were each designed based
on individual exons of the target gene sequence to avoid
amplifying genomic DNA.
During PCR, the probe was hybridized to its comple-
mentary single-strand DNA sequence within the PCR
target. As amplification occurred, the probe was
degraded due to the exonuclease activity of Taq DNA
polymerase, thereby separating the quencher from
reporter dye during extension. During the entire
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tially. A positive result was determined by identifying
the threshold cycle value at which reporter dye emission
appeared above background. For normalization, the
housekeeping gene Peptidyl-prolyl cis-trans isomerasa
(Ppia, Cyclophilin A) was used as the reference gene.
Oxidative Stress Reaction of BIA
The Oxyblot Oxidized Protein Detection Kit was pur-
chased from Chemicon (S7150). The oxyblot procedure
was performed according to the previous study [26].
The 2,4-dinitrophenylhydrazine (DNPH) derivatization
was carried out on 6 μg of protein for 15 min according
to manufacturer’s instructions. One-dimensional electro-
phoresis was carried out on 12% SDS/polyacrylamide gel
after DNPH derivatization. Proteins were transferred to
nitrocellulose membranes which were then incubated in
the primary antibody solution (anti-DNP 1:150) for 2 h,
followed by incubation with second antibody solution
(1:300) for 1 h at room temperature. The washing
procedure was repeated eight times within 40 min.
Immunoreactive bands were visualized by enhanced che-
miluminescence (ECL; Amersham Biosciences) which
was then exposed to Biomax L film (Kodak). For quanti-
fication, ECL signals were digitized using Labwork soft-
ware (UVP). On each gel, a standard control sample was
loaded.
Statistical Analysis
Data were expressed as mean values (mean ± SD). Sta-
tistical analysis was adequately performed by analysis of
variance, followed by Scheffe multiple-comparison post
hoc test. SAS statistical software for Windows version
8.2 was utilized. (SAS institute, Cary, NC). A probability
value < 0.05 was considered statistically significant.
Results
Effect of Combined CsA and EPO on Infarction Area and
Neurological Function after Acute IS
The mortality rate [2 in group 2, 1 in each other group
(i.e. groups 3 to 5)] did not statistically differ among
groups 2 to 5 (p = 0.413). TTC staining of brain tissues
on day 21 after acute IS showed notably reduced BIA in
IS animals treated with CsA (group 3) and EPO (group
4) than in IS animals without treatment (group 2), and
further reduced after combined therapy with CsA and
EPO (group 5) than in group 3 and group 4 (Figure 1).
Corner test showed that, as compared with group 2, a
transient improvement in neurological function was
noted in groups 3 to 5 on day 3 after acute IS (Figure
2A). However, corner test showed the attainment of a
steady state of neurological functional impairment on
day 7 and day 14 following acute IS in groups 2, 3 and
5 but an improvement in neurological function was
noted in group 3 as compared to groups 2, 4 and 5. Sig-
nificant improvement in neurological function became
apparent in groups 3 and 4 as compared with group 2,
and further improvement was noted in group 5 than in
group 2 on day 21 after acute IS (Figure 2B).
Attenuation of Inflammatory Response through
Combined Therapy with CsA and EPO
On day 21 following acute IS induction, the mRNA
expressions of tumor necrosis factor (TNF)-a and
matrix metalloproteinase (MMP)-9, two indicators of
inflammation, were notably higher in group 2 as com-
pared to other groups (Figure 3, A and 3B). In addition,
these two biomarkers were significantly higher in groups
3a n d4t h a ni ng r o u p s1a n d5 .F u r t h e r m o r e ,T N F - a
expression was significantly higher in group 5 as com-
pared with group 1. However, the MMP-9 expression
showed no difference between groups 1 and 5. Addition-
ally, the protein expression of inducible nitric oxide
synthase (iNOS), an index of inflammation, was remark-
ably higher in group 2 than in other groups, notably
higher in groups 3 and 4 than in groups 1 and 5, and
s i g n i f i c a n t l yh i g h e ri ng r o u p5t h a ni ng r o u p1( F i g u r e
4A). Furthermore, the protein expression of NADPH
oxidase 1 (NOX-1), an index of reactive oxygen species
(ROS) formation, was significantly higher in group 2
compared to that in other groups and notably higher in
groups 3 and 4 than in groups 1 and 5, but it was simi-
lar between group 1 and group 5 (Figure 4B). On the
other hand, the protein expression of NOX-2 did not
differ among the 5 groups (Figure 4C). In contrast, the
protein expression of endothelial NOS (eNOS), in index
of anti-inflammation, was remarkably lower in group 2
than in other groups, notably lower in groups 3 and 4
than in groups 1 and 5, but no significant difference was
noted between group 1 and group 5 (Figure 4D).
Enhanced Reduction of Apoptosis and Oxidative Stress by
Combined Treatment with CsA and EPO
On day 21, the mRNA (Figure 3C) and protein expres-
sions (Figure 5A) of caspase 3, one pro-apoptotic index,
w e r es u b s t a n t i a l l yh i g h e ri ng r o u p2t h a ni no t h e r
groups. They were also markedly higher in groups 3 and
4 than in groups 1 and 5, but they did not show signifi-
cant difference between groups 1 and 5. Additionally,
the mRNA (Figure 3D) and mitochondrial protein
expressions (Figure 5B) of Bax, another pro-apoptotic
index, were substantially higher in group 2 than in other
groups, notably higher in groups 3 and 4 than in groups
1 and 5, and the mitochondrial protein expression sig-
nificantly higher in group 5 than in group 1. However,
the Bax mRNA expression only had a statistical trend of
notably higher in group 5 than in group 1. On the other
hand, the cytosolic protein expression of Bax (Figure
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Page 4 of 14Figure 1 Ratios of infarct area to total coronal sectional area using TTC staining. (A to E) Identification of gross infarct area (green circles)
in animals with B) ischemic stroke (IS) (group 2), C) IS + cyclosporine (CsA) (group 3), D) IS + erythropoietin (EPO) (group 4) and E) IS +
combined CsA & EPO (group 5), respectively. (F) Significantly lower ratio of infarct area to total coronal sectional area in group 5 than in group
2, 3, and 4, and notably lower in group 3 and 4 than in group 2 (n = 6 for each group). * vs. other groups, p < 0.0001 (using ANOVA). Symbols
(*, †, ‡) indicate significance (at 0.05 level) (by Scheffe multiple-comparison post hoc test).
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Page 5 of 14Figure 2 Assessment of neurological function with Corner test. A) T h er e s u l t so fC o r n e rt e s t( n=1 0 )o nd a y0 ,1 ,3 ,7 ,1 4 ,a n d2 1a f t e r
acute IS, showing a steady state of neurological functional impairment on day 3 to 14 following acute IS in group 2, 3, 4, and 5. B) Significant
improvement in neurological function noted in group 3, 4, and 5 compared with group 2 on day 21 after acute IS, and further improvement
observed in group 5 compared with group 3 and 4. * vs. other groups, p < 0.001 (at day 21). Symbols (*, †, ‡) indicate significance (at 0.05 level)
(by Scheffe multiple-comparison post hoc test).
Figure 3 Profiles of mRNA expression in infarct area. A) Tumor necrosis factor (TNF)-a mRNA expression was remarkably higher in group 2
than in other groups, notably higher in group 3 and 4 than in group 1 and 5, and significantly higher in group 5 than in group 1. † vs. other
groups, p < 0.0001 (ANOVA test). B) Matrix metalloproteinase (MMP)-9 mRNA expression markedly increased in group 2 than in other groups,
notably increased in group 3 and 4 than in group 1 and 5, but no remarkable difference between group 3 and 4 or between group 1 and 5. †
vs. other groups, p < 0.0001 (ANOVA test). C) & D) Substantially higher mRNA expressions of caspase 3 (C) and Bax (D) in group 2 than in other
groups, and significantly higher in group 3 and 4 than in group 1 and 5, but no notable difference between group 3 and 4 or between group 1
and 5. † vs. other groups, p < 0.0001 (ANOVA test). E) & F) Significantly lower mRNA expressions of Bcl-2 and PGC-1a in group 2 than in other
groups and markedly lower in group 3 and 4 than in group 1 and 5, but no difference between group 3 and 4 and between group 1 and 5. †
vs. other groups, p < 0.0001 (ANOVA test). G) Substantially higher mRNA expression of aquaporin-4 (AQP-4) in group 2 than in other groups and
remarkably higher in group 3 and 4 than in group 1 and 5, but no significant difference between group 3 and 4 or between group 1 and 5. †
vs. other groups, p < 0.001 (ANOVA test). Symbols (*, †, ‡, §) from A) to G) indicate significance (at 0.05 level) (by Scheffe multiple-comparison
post hoc test) (n = 6 for each group).
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groups, notably lower in groups 3 and 4 than in group
1 ,b u ti ts h o w e dn od i f f e r e n c eb e t w e e ng r o u p s1a n d5
or among groups 3, 4 and 5.
The mRNA (Figure 3E) and protein expressions (Fig-
ure 5D) of Bcl-2, an indicator of anti-apoptosis, were
notably lower in group 2 than in other groups. The
expressions were also significantly lower in groups 3
and 4 than in groups 1 and 5 but without notable differ-
ence between groups 1 and 5. Furthermore, TUNEL
assay (Figure 6) showed that the number of apoptotic
nuclei was substantially increased in group 2 than in
other groups, remarkably higher in groups 3 and 4 than
in groups 1 and 5, and significantly higher in group 5
than in group 1.
On day 21 following acute IS induction, Western blot-
ting (Figure 7, A and 7B) demonstrated a significantly
higher oxidative index in mitochondria in group 2 than
in other groups. The oxidative index was also signifi-
cantly higher in groups 3 and 4 than in groups 1 and 5,
and notably higher in group 5 compared with that in
group 1.
Better Preservation of Mitochondrial Cytochrome C after
Combined Therapy with CS and EPO against Acute IS
The protein expression of cytochrome C in mitochon-
dria (Figure 7C) was significantly reduced in group 2
compared to that in other groups, significantly lower in
groups 3 and 4 than in group 1, but it did not differ
among groups 3 to 5, or between groups 1 and 5. In
contrast, its cytosolic expression (Figure 7D) was signifi-
cantly enhanced in group 2 compared with other
groups, significantly elevated in groups 3 and 4 than in
groups 1 and 5, but it did not differ between group 1
group 5. These findings indicate that the expression of
Figure 4 Protein expression levels of inflammation and
oxidative stress-related in infarct area. A) and B) Remarkably
elevated protein expressions of inducible nitric oxide synthase
(iNOS) (A) and NADPH oxidase 1 (NOX-1) (B) in group 2 than in
other groups, notably higher in group 3 and 4 than in group 1 and
5, significantly increased in group 5 than in group 1, but no
difference between group 3 and 4. † vs. other groups, p < 0.001
(ANOVA test). C) No significant difference in NOX-2 protein
expression among all groups. D) Remarkably lower protein
expressions of endothelial (e)NOS in group 2 than in other groups,
notably lower in group 3 and 4 than in group 1 and 5, but no
difference between group 3 and 4. Similar eNOS protein expression
noted between group 1 and group 5. † vs. other groups, p < 0.001
(ANOVA test). Symbols (*, †, ‡, §) from A) to D) indicate significance
(at 0.05 level) (by Scheffe multiple-comparison post hoc test) (n = 6
for each group).
Figure 5 Protein expression levels of apoptosis-related in
infarct area. A) Caspase 3 protein expression was notably higher in
group 2 than in other groups, notably higher in group 3 and 4, but
no significant difference between group 3 and 4 and between
group 1 and 5. † vs. other groups, p < 0.0001 (ANOVA test). B)
Significantly higher mitochondrial protein expression of Bax in
group 2 than in other groups. Significant elevation also noted in
group 3 and 4 compared with that in group 1 and 5, and notably
higher in group 5 than in group 1, but no remarkable difference
between group 3 and 4. † vs. other groups, p < 0.001 (ANOVA test).
C) Cytosolic protein expression of Bax substantially lower in group 2
than in other groups, but no difference between group 1 and 5 or
among group 3, 4, and 5. † vs. other groups, p < 0.001 (ANOVA
test). D) Bcl-2 protein expression notably lower in group 2 than in
other groups, significantly lower in group 3 and 4 than in group 1
and 5, but no significant difference between group 1 and 5 or
between group 3 and 4. † vs. other groups, p < 0.001 (ANOVA test).
Symbols (*, †, ‡,§ )i nA) to D) indicate significance (at 0.05 level)
(by Scheffe multiple-comparison post hoc test).
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Page 7 of 14Figure 6 TUNEL assay for indentifying apoptotic nuclei in brain infarct area. The number of apoptotic nuclei (yellow arrows) notably
higher in group 2 (B) than in group 1 (A), group 3 (C), group 4 (D) and group 5 (E), significantly higher in group 3 and 4 than in group 1 and
5, and significantly higher in group 5 than in group 1, but no significant difference between group 3 and 4. Scale bars in right lower corner
represent 20 μm (400x). † vs. other groups, p < 0.001 (ANOVA test). Symbols (*, †, ‡, §) indicate significance (at 0.05 level) (by Scheffe multiple-
comparison post hoc test).
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Page 8 of 14cytochrome C, an index of energy supply and storage in
mitochondria, was relatively well-preserved in groups 3
to 5 as compared with that in group 2, and was more
p r e s e r v e di ng r o u p5a sc o m p a r e dt og r o u p s3a n d4 .
Additionally, the increase in cytosolic cytochrome C
content also suggests significant mitochondrial damage
with cytochrome C release into the cytosol in the brain
of group 2 animals.
Further Reduction in Expressions of Glial Fibrillary Acid
Protein (GFAP) and Aquaporin-4 (AQP-4) and Preservation
of Neural PGC-1a in Infarct Brain after Combined Therapy
with CsA and EPO
The mRNA expression of peroxisome proliferator-acti-
vated receptor-g coactivator-1a (PGC-1a)( F i g u r e3 F ) ,
which is a transcriptional coactivator for regulating lipid
catabolism, oxidative metabolism, mitochondrial meta-
bolism and biogenesis, was notably lower in group 2
than in other groups and significantly lower in groups 3
a n d4t h a ni ng r o u p s1a n d5 ,b u ti td i dn o td i f f e r
between groups 3 and 4 or between groups 1 and 5.
Conversely, AQP-4 mRNA expression (Figure 3G), an
indicator of brain edema, was substantially increased in
group 2 compared to that in other groups and notably
increased in groups 3 and 4 than in groups 1 and 5, but
it was similar between groups 3 and 4 or between
groups 1 and 5.
Immunofluorescent staining showed that the expres-
sion of GFAP (Figure 8, A-E, white arrows), the princi-
pal intermediate filament of mature astrocytes, was
remarkably higher (Figure 8G) in group 2 compared to
that in other groups, significantly higher in groups 3
and 4 than in groups 1 and 5, and notably higher in
group 5 compared to that in group 1. In addition, AQP-
4 (Figure 8, A-E, yellow arrows) was substantially
i n c r e a s e d( F i g u r e8 F )i ng r o u p2t h a ni no t h e rg r o u p s ,
notably increased in groups 3 and 4 than in groups 1
and 5, but no significant difference was noted between
groups 1 and 5. Conversely, neuronal expression of
PGC-1a, an index of mitochondrial integrity (Figure 9,
A-E, doubly labeled by yellow and white arrows), was
remarkably lower (Figure 9G) in groups 2 than in other
groups, notably lower in group 3 and 4 than in groups 1
and 5, and significantly lower in group 5 as compared
with that in group 1.
Discussion
Combined Therapy with Cyclosporine and EPO Provided
Additional Benefits of Limiting Brain Infarct Size and
Improving Recovery of Neurological Function
The most important finding in the current study was
that TTC staining of the brain tissue on day 21 after
acute IS showed that the BIA was remarkably reduced
in IS animals treated with either CsA (group 3) or EPO
(group 4) than in IS animals without treatment (group
2). These findings imply that CsA or EPO therapy sig-
nificantly reduce BIA after IS. Moreover, corner test
showed a significant improvement in neurological func-
t i o ni ng r o u p s3a n d4t h a ni ng r o u p2o nd a y2 1a f t e r
acute IS. Interestingly, previous studies [12-15] have
demonstrated that EPO therapy significantly reversed
ischemia-related left ventricular dysfunction. In concert
with this finding, previous investigations by other
authors and our recent studies [16,24] have also shown
that EPO therapy markedly attenuated BIA and
improved neurological function in rat after acute IS.
Furthermore, our recent clinical trial [17] has shown
that EPO therapy substantially improved 90-day major
adverse neurological event. Our findings, therefore, are
consistent with those of previous studies [12-17].
Figure 7 Oxidative index and protein expression levels of
cytochrome (Cyt) C in brain infarct area. A) Oxidative index
determination by Western blotting of brain infarct area (BIA) (n = 6),
showing notably increased oxidative index, protein carbonyls, in BIA
of group 2 compared with other groups, notably higher in group 3
and 4 than in group 1 and 5, and significantly higher in group 5
than in group 1 on day 21 following acute IS. B) † vs. other groups,
p < 0.0001 (ANOVA test). C) Protein expression of mitochondrial
cytochrome C in brain infarct area (n = 6) markedly lower in group
2 than in other groups, notably lower in group 3 and 4 than in
group 1, but no notable difference among group 3,4, and 5, or
between group 1 and 5. † vs. other groups, p < 0.01 (ANOVA test).
D) Protein expression of cytosolic cytochrome C in BIA (n = 6)
markedly higher in group 2 than in other groups, notably higher in
group 3 and 4 than in group 1 and 5, but no significant difference
between group 3 and 4, or between group 1 and 5. † vs. other
groups, p < 0.01 (ANOVA test). Symbols (*, †, ‡, §) from B) to D)
indicate significance (at 0.05 level) (by Scheffe multiple-comparison
post hoc test).
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Page 9 of 14Figure 8 Distribution of glial fibrillary acid protein (GFAP) and aquaporin-4 (AQP-4) in brain infarct area. A) to E) Immunofluorescent
staining (400 x) of glial fibrillary acid protein (GFAP) (white arrows) and aquaporin-4 (AQP-4) (yellow arrows) in brain infarct area (n = 6). Both
numbers of GFAG and AQP-4 remarkably higher in group 2 than in other groups, notably higher in group 3 and 4 than in group 1 and 5, and
significantly higher in group 5 than in group 1. F) and G) † vs. other groups, p < 0.0001 (ANOVA test). Symbols (*, †, ‡,§ )i n(F) and (G) indicate
significance (at 0.05 level) (by Scheffe multiple-comparison post hoc test). Scale bars in right lower corner represent 20 μm.
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Page 10 of 14Figure 9 Distribution of Neural peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a) in brain infarct area. A) to E)
Immunofluorescent staining (400 x) of PGC-1a (yellow arrows) and neuron (white arrows) in brain infarct area (n = 6). Both numbers of PGC-1a
+ cells and neurons remarkably lower in group 2 than in other groups, significantly lower in group 3 and 4 than in group 1 and 5, and
significantly reduced in group 5 compared with group 1. F) and G) † vs. other groups, p < 0.0001 (ANOVA test). Symbols (*, †, ‡,§ )i n(F) and
(G) indicate significance (at 0.05 level) (by Scheffe multiple-comparison post hoc test). Scale bars in right lower corner represent 20 μm.
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Page 11 of 14Interestingly, as compared with EPO, CsA therapy
(group 4) offered similar protection of the brain against
infarction/ischemia in the current study. Recent studies
[21,22,27,28] have shown that CsA therapy notably
reduced infarction size and improved ischemia-related
organ function in both animal experiments and clinical
observational studies. Thus, our findings strengthen
those of the studies [21,22,27,28]. Of importance is that,
as compared with those group 3 and group 4, combined
therapy with CsA and EPO (group 5) further attenuated
BIA. These findings may explain the enhanced improve-
ment in neurological function in group 5 animals as
compared with those in group 3 and group 4. In this
way, the results of the present investigation extend the
findings of previous studies [12-17,21,22,27,28].
Combined therapy with EPO and tissue plasminogen
activator (tPA) for patients after acute IS has been
recently reported by Ehrenreich et al. [29]. Failure in
demonstrating additional benefits of combining EPO
with tPA in improving clinical outcome of patients with
acute IS as compared with placebo-controls in that clini-
cal trial [29] may be due to tPA-associated bleeding
complication that outweighed the benefit of EPO treat-
ment [17].
Combined Therapy of CsA and EPO Further Limited
Inflammatory Reaction, Generation of Reactive Oxygen
Species, and Oxidative Stress after Acute IS
Abundant studies have shown that innate immune
mechanisms are rapidly activated following acute arterial
obstructive syndrome (i.e. tissue injury and necrosis)
which, in turn, initiate the complement cascade, inflam-
matory reaction, and ROS generation [16,23,30,31]. Addi-
tionally, inflammatory components of the ischemic
cascades further perpetuate cellular apoptosis and necro-
sis in ischemic region [15,16,22,23,30-33]. One important
finding of the present study is that the inflammatory
responses were markedly increased in group 2 animals
than in those in groups 3 to 5 on day 21 after acute IS.
Moreover, both ROS generation (NOX-1) and oxidative
stress were remarkably enhanced in group 2 animals than
in other groups on day 21 after acute IS. Another intri-
guing finding of the current study is that the expressions
of anti-inflammatory protein, eNOS, was substantially
reduced in group 2 than in other groups. Additional
important finding also includes the remarkably increased
number of GFAP-positive cells, an indicator of inflamma-
tory cells in ischemic brain, in group 2 and notable
reduction in groups 3 to 5 after treatment. Therefore,
our findings, in addition to corroborating those of pre-
vious reports [15,16,22,23,30-33], could at least partially
explain the poorer prognostic outcome in group 2 ani-
mals compared with those in groups 3 to 5. Besides, the
results of our study may support the proposal that both
CsA and EPO therapy are equally effective in protecting
the brain against ischemic damage after acute IS through
suppressing inflammation, generation of ROS, and oxida-
tive stress. Of importance is that combined therapy with
CsA and EPO was found to be superior to either one
alone in inhibiting the production of inflammatory bio-
markers, ROS, and oxidative stress.
Possible Mechanisms of CsA and EPO Underlying
Improved Outcome after Acute Ischemic Stroke
The key role of EPO therapy in improving outcome after
acute IS has been mainly attributed to attenuation of
inflammation, oxidative stress, cellular apoptosis,
and enhancement of angiogenesis and neurogenesis
[16,17,24,34]. On the other hand, inhibition of inflamma-
tion, oxidative stress, cellular apoptosis, and mPTP open-
ing have been proposed to be the underlying mechanisms
involved in CsA-mediated protection against ischemia-
reperfusion organ dysfunction [18-20,27,28]. In the cur-
rent study, not only were the inflammatory and oxidative
cascades found to be substantially diminished, but the
apoptotic markers were also substantially attenuated after
CsA and EPO therapy. Accordingly, the anti-apoptotic
index (Bcl-2) was notably enhanced following combined
therapy. In addition, reduction in the number of AQP4+
cells and preservation of the number of PGC-1a+n e u -
rons in BIA were observed after CsA and EPO treatment.
Moreover, mitochondrial cytochrome C was better pre-
served in treated than in untreated animals after acute IS.
Therefore, our findings not only extend those of previous
studies [16-20,24,27,28,34], but they also provide novel
information on the superiority of combined therapy with
CsA and EPO compared with either agent alone in the
treatment of acute IS in an experimental setting. In con-
sideration of the fact that both EPO and CsA are fre-
quently and separately used in our daily clinical practice
for variety of disease entities, this pre-clinical information
may warrant the need for a prospective clinical trial in
evaluating the benefit of combined therapy with CsA and
EPO which have been widely used in different clinical
settings after acute IS.
Study Limitation
This study has limitations. First, since the current study
period was only 21 days, the long-term effect of com-
bined therapy with CsA and EPO on sensorimotor func-
tion in this experimental setting is unknown. Second,
this study did not investigate the safety of CsA dosage
so that the side-effects of CsA therapy remain unclear.
A balance between the benefits and risks of CsA use,
therefore, is still a major concern regarding the clinical
use of CsA in the setting of acute IS.
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Page 12 of 14Conclusion
The results of the present study suggest that combined
therapy with CsA and EPO is superior to either agent
alone in reducing BIA and improving neurological func-
tion after acute IS. The proposed mechanisms underly-
ing the potential impacts of combined CsA and EPO in
rats after IS have been summarized in Figure 10.
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